Abstract:Insulin-degrading enzyme (IDE) is involved in the clearance of insulin and amyloid β. This is necessary to maintain proper blood sugar levels and to prevent accumulation of amyloid β in the brain. The crystal structure of IDE in complex with four substrates has now been determined, revealing the molecular basis for substrate recognition. This should aid the design of IDE-based drugs for Alzheimer's disease and type II diabetes. The crystal structure of insulin-degrading enzyme (IDE) in complex with four substrates is presented, revealing the molecular basis for substrate recognition by IDE. Insulin-degrading enzyme (IDE), a Zn2+-metalloprotease, is involved in the clearance of insulin and amyloid-β (refs 1–3). Loss-of-function mutations of IDE in rodents cause glucose intolerance and cerebral accumulation of amyloid-β, whereas enhanced IDE activity effectively reduces brain amyloid-β (refs 4–7). Here we report structures of human IDE in complex with four substrates (insulin B chain, amyloid-β peptide (1–40), amylin and glucagon). The amino- and carboxy-terminal domains of IDE (IDE-N and IDE-C, respectively) form an enclosed cage just large enough to encapsulate insulin. Extensive contacts between IDE-N and IDE-C keep the degradation chamber of IDE inaccessible to substrates. Repositioning of the IDE domains enables substrate access to the catalytic cavity. IDE uses size and charge distribution of the substrate-binding cavity selectively to entrap structurally diverse polypeptides. The enclosed substrate undergoes conformational changes to form β-sheets with two discrete regions of IDE for its degradation. Consistent with this model, mutations disrupting the contacts between IDE-N and IDE-C increase IDE catalytic activity 40-fold. The molecular basis for substrate recognition and allosteric regulation of IDE could aid in designing IDE-based therapies to control cerebral amyloid-β and blood sugar concentrations1,8,9.

Degradation of Alzheimer’s Amyloid-β by a Catalytically Inactive Insulin-Degrading Enzyme

Structures of Human Insulin-Degrading Enzyme Reveal a New Substrate Recognition Mechanism

Characteristics of Insulin-degrading Enzyme in Alzheimer's Disease: A Meta-Analysis.

Insights into Non-Proteolytic Inhibitory Mechanisms of Polymorphic Early-Stage Amyloid β Oligomers by Insulin Degrading Enzyme

Ensemble cryoEM elucidates the mechanism of insulin capture and degradation by human insulin degrading enzyme

Structure of Substrate-free Human Insulin-degrading Enzyme (IDE) and Biophysical Analysis of ATP-induced Conformational Switch of IDE

Insulin‐degrading enzyme: an ally against metabolic and neurodegenerative diseases

Insulin-degrading enzyme sorting in exosomes: a secretory pathway for a key brain amyloid-beta degrading protease.

Insulin degrading enzyme activity selectively decreases in the hippocampal formation of cases at high risk to develop Alzheimer's disease.

Identification of Indole-Based Activators of Insulin Degrading Enzyme.

Effect of Berberine Chloride on Expression of Insulin Degrading Enzyme in Rat Models with AD

In Vitro Studies on Accelerating the Degradation and Clearance of Amyloid-β Fibrils by an Antiamyloidogenic Peptide.

Role of Aβ-degrading enzymes in pathogenesis and treatment of Alzheimer's disease

Microglia Do Not Take Up Soluble Amyloid-beta Peptides, But Partially Degrade Them by Secreting Insulin-degrading Enzyme

The core sequence of PIF competes for insulin/amyloid β in insulin degrading enzyme: potential treatment for Alzheimer's disease

Structure-activity Relationships of Imidazole-Derived 2-[N-carbamoylmethyl-alkylamino]acetic Acids, Dual Binders of Human Insulin-Degrading Enzyme.

The Extracellular Matrix Enriched with Membrane Metalloendopeptidase and Insulin-Degrading Enzyme Suppresses the Deposition of Amyloid-Beta Peptide in Alzheimer's Disease Cell Models

Degradation and/or Dissociation of Neurodegenerative Disease-Related Factor Amyloid-β by a Suspension Containing Calcium Hydrogen Carbonate Mesoscopic Crystals

Iodoacetamide Attenuates Cognition Impairment and Amyloid Deposit in an AD Rat Model

Insulin degrading enzyme contributes to the pathology in a mixed model of Type 2 diabetes and Alzheimer’s disease: possible mechanisms of IDE in T2D and AD

Down‐regulation of Insulin‐degrading Enzyme by Presenilin 1 V97L Mutant Potentially Underlies Increased Levels of Amyloid Beta 42